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Introduction: There are little data available regarding compliance with the National Comprehensive
Cancer Network (NCCN) guidelines. We investigated variation in the management of pancreatic cancer
(PC) among large hospitals in California, USA, specifically to evaluate whether compliance with NCCN
guidelines correlates with patient outcomes.
Methods: The California Cancer Registry was used to identify patients treated for PC from 2001 to 2006.
Only hospitals with  400 beds were included to limit evaluation to centres possessing resources to
provide multimodality care (n = 50). Risk-adjusted multivariable models evaluated predictors of adherence
to stage-specific NCCN guidelines for PC and mortality.
Results: In all, 3706 patients were treated for PC in large hospitals during the study period. Compliance
with NCCN guidelines was only 34.5%. Patients were less likely to get recommended therapy with
advanced age and low socioeconomic status (SES). Using multilevel analysis, controlling for patient
factors (including demographics and comorbidities), hospital factors (e.g. size, academic affiliation and
case volume), compliance with NCCN guidelines was associated with a reduced risk of mortality [odds
ratio (OR) for death 0.64 (0.53–0.77, P < 0.0001)].
Conclusions: There is relatively poor overall compliance with the NCCN PC guidelines in California's
large hospitals. Higher compliance rates are correlated with improved survival. Compliance is an impor-
tant potential measure of the quality of care.
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Introduction
Quality is the new mantra of American medicine and perhaps, in
particular, American surgery. In fact, the American College of
Surgeons’ current slogan is ‘Inspiring Quality: Highest Standards,
Better Outcomes.’1 But health care quality has proved challenging
to define, much less improve. A variety of quality improvement
programmes have been developed in order to meet this need: the
National Surgical Quality Improvement Program (NSQIP), the
Surgical Care Improvement Project (SCIP), the University Health
Consortium Quality and Accountability Program (UHC-QAP)
and the Leapfrog Group, among others. Each seeks to address one
or more aspects of the three domains of healthcare quality mea-
sures: structure, process and outcome.2 However, it has often
proven surprisingly difficult to translate structure or process
quality measure to improved outcomes.3,4 Quality improvement is
particularly challenging for complex cancer care, where long-term
outcomes result from high-quality care across a spectrum of spe-
cialties from radiology to surgery to medical and radiation oncol-
ogy.5 For complex cancer operations, individual hospital volume
has been the dominant predictor of outcomes.6 The positive
correlation between volume and outcome was demonstrated for
operations for pancreatic cancer (PC) more than a decade ago,7,8
yet there has been only a modest shift towards the use of higher
volume centres for care.9 Thus, assessment of the quality of the
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care of patients with PC must look beyond volume to describe
other factors that correlate with optimal outcomes.
In an effort to improve the quality of cancer care, the National
Comprehensive Cancer Network (NCCN) began in the 1990s to
publish clinical practice guidelines that encompass the diagnosis,
treatment and palliation of common cancers based on the best
available evidence and expert consensus. These guidelines are
updated regularly as new evidence emerges and practice evolves,
and are the most widely recognized cancer clinical care guidelines
in the United States. While evidence-based practice guidelines are
becoming more and more standardized as a means of quality
improvement,10 the effectiveness of guidelines depends not solely
on the quality of the guideline but also on dissemination and
compliance.11 Broadly speaking, research into the effect of clinical
practice guidelines on patient outcomes is still in its infancy,12 and
only a small number of publications are available that specifically
investigate the impact of compliance with NCCN guidelines13–15
The aim of the present study was to assess rates of compliance
with NCCN guidelines and to analyse the impact of adherence on
outcomes. We hypothesized that there is significant variation in
the care of patients with PC, and that this variation impacts
patient outcomes. To test this hypothesis, we performed a retro-
spective cohort study examining compliance with the NCCN
guidelines for the management of PC in large California hospitals
and the effect compliance had on patient.
Methods
Sources of data
The California Cancer Registry (CCR)16 data were linked to the
California Office of Statewide Health Planning and Development
(OSHPD) patient discharge abstracts. This dataset was subse-
quently linked to hospital characteristics from the publicly avail-
able California Hospital Annual Financial Datafile (HAFD).17
The CCR contains data collected via a state-wide cancer-
reporting programme mandated by the California Health and
Safety Code (sections 103875–103885), and managed by the Cali-
fornia Department of Health Services (DHS) in collaboration
with the Public Health Institute and eight regional cancer regis-
tries.16 California state law requires that all hospitals, physicians
and certain other health care providers report every clinical
encounter where cancer is the primary diagnosis regardless of
treatment administered during the encounter. All relevant clinical,
radiological and pathological data are reported, which decreases
the loss to follow-up rate for patients who complete treatment
within the state, even if primary and subsequent treatments are
administered in different hospitals. The registry contains fewer
than 3% missing race data; and fewer than 3% of records obtained
from death certificates. In addition to detailed information about
the individual tumours, with grade, stage and select molecular
marker data, the database also contains census block group level
sociodemographic data, including a validated composite socio-
economic status (SES) score.18,19
The California OSHPD patient discharge database compiles
data for all discharges from more than 400 general, acute, non-
federal hospitals in the state. In addition to the principal diagnosis
(reason for admission) and the principal procedure, coded using
the International Classification of Diseases-9th Clinical Modifica-
tion (ICD-9-CM), the database also contains coding for up to 24
additional diagnoses (secondary diagnoses) and up to 19 addi-
tional procedures performed during the index hospitalization.
California is one of only two databases, nationwide, to historically
require all secondary diagnoses to be entered with concomitant
coding for whether the condition was present on admission
(CPOA). CPOA coding allows for distinction between co-
morbidities and hospital acquired conditions (i.e. complications),
and therefore facilitates risk adjustment of outcomes in multivari-
able models. The database also contains demographic informa-
tion including age at diagnosis, gender and insurance status.
Hospital volume can be derived based on the total number of
discharges for a particular diagnosis aggregated at the hospital
level.
Data from the CCR are linked to OSHPD data using a proba-
bilistic linkage method employing day, month and year of birth in
conjunction with the patient’s social security number. The linkage
was performed by the staff at the CCR then stripped of linking
variables before disclosure to the investigators. OSHPD-assigned
unique hospital identifiers were then used to link the CCR-
OSHPD data to California Hospital Annual Financial Data
(HAFD). The HAFD contains hospital level characteristics such as
geographic location, Medicaid utilization rate, hospital ownership
and teaching hospital status as designated by the state.
The study was approved by the California Committee for the
Protection of Human Subjects (CPHS), the California Cancer
Registry and the Stanford University Institutional Review Board.
Study cohort
All patients admitted with the diagnosis of pancreatic adenocar-
cinoma (principal diagnosis code 157.0–157.3, 157.8) to Califor-
nia’s general, acute, non-federal hospitals between 2001 and 2006,
inclusive, were identified in the linked database described above.
In order to limit the analysis to larger hospitals which would likely
possess the personnel and resources to deliver multidisciplinary
care, we only included hospitals with more than 400 beds. Fifty-
two hospitals were identified with 400 beds; two were excluded
because they are rehabilitation facilities. Eight academic hospitals
were identified by affiliation with a medical school, whereas
‘teaching hospitals’ are designated in the dataset by affiliation with
resident training (n = 19).
Compliance
In order to assess compliance during the years 2001–6, we started
with the 2000 NCCN guidelines.20 Of note, cancer stage in the
2000 NCCN guidelines relied on the 5th edition (1997) of the
American Joint Committee on Cancer (AJCC) and the Interna-
tional Union Against Cancer (UICC) TNM system.21 The prin-
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ciple difference between the AJCC 5th edition and the subsequent
6th and 7th (current) editions is the definition of T3 and T4 tumors:
5th edition: T3 Tumour extends into any of the following:
duodenum, bile duct and peripancreatic tissues
T4 Tumour extends directly into any of the following:
stomach, spleen, colon and adjacent large vessels
6/7th editions: T3 Tumour extends beyond the pancreas but
without involvement of the celiac axis or superior mesenteric
artery
T4 Tumour involves the celiac axis or superior mesenteric
artery (unresectable)
Thus, in the newer editions, T4 tumours are explicitly unresec-
table by consensus definitions of resectability,22 while a small
number of patients staged as T4 (and thus Stage VIa) according to
the 5th edition would have tumours that would have been deemed
resectable by experienced pancreatic surgeons (e.g. requiring
portal vein resection/reconstruction or en-bloc resection of adja-
cent stomach, adrenal, etc.). However, appropriate resection of
an adjacent portal vein or adjacent organs applies to a very
small number patients on a population basis and thus, for our
analysis, we assumed that T4 (and thus all stage IV) tumours were
unresectable.
The NCCN guidelines do allow variation in care and evolve
over time. For example, while adjuvant treatment of resected PC is
standard, neoadjuvant care is explicitly mentioned as an accept-
able alternative. In addition, the allowable chemotherapy and
radiotherapy has evolved. The 2000 guidelines recommend gem-
citabine for unresectable disease23 and 5FU-based chemoradiation
for all resected tumours (beyond Tis) based on the GITSG data.24
However, subsequent modifications have included alternative
regimens (e.g. adjuvant gemcitabine based on CONKO-125). The
CCR data set includes a data point indicating that chemotherapy
was recommended but not administered or the patient declined.
These patients were recorded as having received the chemotherapy
for our analysis to give the treating facility credit for the recom-
mendation. While radiation was not required for compliant care
at any stage, chemoradiation was considered compliant if admin-
istered in an adjuvant or neoadjuvant setting or with palliative
intent in stage IV disease. Four patients were coded as having
received radiation but no chemotherapy of any kind. We assumed
that these patients had received 5FU concomitantly with the
radiation (but this was omitted in the coding), and coded them as
having received chemoradiation for our analysis. Surgical proce-
dures were characterized by ICD-9 codes. Operations assumed to
have been performed with curative intent included all pancreate-
ctomies: 52.5 (52.51-3, 52.59), 52.6, 52.7. Palliative procedures
included 51.87 (endoscopic biliary stent), percutaneous biliary
drains (51.98), gastroenterostomy (44.38, 44.39), gastrostomy
(43.11, 44.32), biliary anastomoses (51.36, 51.39) and nerve block
(04.49) that were not associated with a resection. In order to be
inclusive given the variety of options available to clinicians and to
reflect evolving clinical practice, we defined compliance in very
permissive terms:
Stage NCCN-based definition of compliant treatment
O Surgery
I Surgery + chemotherapy or chemoradiation (adjuvant or
neoadjuvant)
II Surgery + chemotherapy or chemoradiation (adjuvant or
neoadjuvant)
III Surgery + chemotherapy or chemoradiation (adjuvant or
neoadjuvant)
IV Chemotherapy  palliative procedures  palliative
radiotherapy
Data analysis
Analyses were performed using SAS 9.2 for Windows (SAS Insti-
tute Inc., Cary, NC, USA), and a two-sided P < 0.05 was considered
statistically significant. Kaplan–Meier curves were generated to
survival based on stage, compliance, academic volume and annual
hospital volume. Multivariable and multilevel logistic regression
analyses were used to calculate the adjusted OR predicting
compliance (individual patient receipt of compliant care) and
mortality as a function of patient characteristics and hospital
characteristics (because compliance was defined by stage, it was
excluded from the modelling). The same multivariable modelling
was then used to calculate the adjusted OR for mortality as a
function of patient characteristics, cancer stage and hospital char-
acteristics. Patient level predictor variables included age, race/
ethnicity, gender, type of insurance and socioeconomic level.
Severity of co-morbid illness was defined using the Deyo-
modified Charlson comorbidity index26,27 for each individual
patient. Hospital characteristics evaluated for the study included
annual PC volume, teaching status and academic affiliation. Case
volume was divided into terciles (low 1–15; medium 16–25; high
> 25) based on the number of annual discharges with a primary
diagnosis of PC during the study period. All other hospital vari-
ables were defined in the HAFD.
Results
During the study period, 17 970 patients were treated for PC in
397 hospitals. Of these, 5690 (32%) were treated in the 50 hospi-
tals that had 400 or more beds. After excluding 1984 patients with
missing staging information, 3706 patients remained as the study
cohort (Table 1). The stage distribution was as follows: 17 Stage 0
(0.5%), 291 stage I (7.9%), 952 stage II (25.7%), 395 stage 3
(10.7%) and 2051 stage IV (55.3%). The 5-year survival for the
entire cohort was 23%.
Care that was compliant with the NCCN guidelines was deliv-
ered to just 34.5% of patients overall, breaking down into 88.2%
of Stage 0, 18.6% Stage I, 33.8% Stage II, 20.8% Stage III and
39.4% Stage IV. Among the 50 large hospitals in California, com-
pliance ranged from 5% to 57%. Figure 1 shows the distribution
of compliance of all 50 hospitals according to rank (highest
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compliance on left). The red bars indicate case volume, demon-
strating that several of the higher volume hospitals nonetheless
had poor compliance.
Of patients with stage I–III cancer just 28% received compliant
care (surgery and chemotherapy or chemoradiation), 27%
received no treatment or palliative intervention only, 21% under-
went resection but received no adjuvant or neoadjuvant therapy
and 24% received chemotherapy or chemoradiation for their
localized pancreatic disease. Patients with stage IV disease received
compliant care in 39% of cases; however, more than half (52%)
received no treatment or palliative intervention only, and 9%
underwent a formal pancreatectomy (+/- adjuvant therapy) in
spite of having advanced disease.
A multilevel logistic regression analysis was performed to
predict compliant care (Table 2). After adjusting for patient and
hospital factors, we found that patients older than 65 were less
likely to get compliant care, as were patients of Hispanic origin
and those of lower SES. Charlson’s co-morbidity score was
not uniformly associated with receipt of compliant care. While
patients with Charlson scores of 1 or 2 (vs. 0) were less likely to
get compliant care, patients with higher co-morbidity scores
(Charlson 3, 41% of all patients) were more likely to receive
compliant care. Thus, co-morbidities as measured by the
Charlson composite score did not appear to be a strong predic-
tor of the care provided. Although patients at academic and
teaching hospitals were not more likely to receive compliant care
on multilevel analysis, high-volume centres were more likely
to deliver NCCN compliant care than mid- and low-volume
centres.
Patients who received compliant care had reduced unadjusted
mortality compared with those who received non-compliant care
(Fig. 2a), with a median survival of 8.8 [95% confidence interval
(CI): 8.3–9.4] months vs. 3.9 months (95% CI: 3.6–4.4) (P 
0.0001). This effect was more pronounced for Stages I–III than
Stage IV (Fig. 2b). Survival was also better at academic centres
than non-academic centres [median 4.0 (3.8–4.3) vs. 8.1 (7.2–
9.0), P < 0.0001] and at high-volume centres > 25 cases/years
compared with mid- and low-volume centres [median 7.2 (6.5–
7.7), 3.9 (3.5–4.3) and 3.0 (2.7–3.4) respectively, P < 0.0001, com-
paring high to mid and low]. Of note, a similar magnitude
survival benefit was seen for compliant care in an analysis of the
nearly 18 000 patients treated for PC (irrespective of hospital
size), although the survival curves for both compliant and non-
compliant care patients were poorer in the hospitals with < 400
beds (data not shown).
Table 3 shows the multilevel logistic regression analysis for pre-
dictors of mortality. In spite of controlling for patient demo-
graphics, co-morbidities and cancer stage, guideline compliance
was associated with a 36% decreased odds of mortality (OR = 0.64
95% CI 0.53–0.77, P < 0.0001). Patient factors predictive of mor-
tality included age greater than 65 years, a low SES and advancing
cancer stage. Care at academic centres was associated with a
decreased risk of mortality (OR 0.66; 95% CI 0.51–0.84; P <
0.005). Similarly, patients who received care at high-volume
centres had significantly decreased mortality. In fact, patients who
received care at low- and mid-volume centres had a significantly
increased odds of mortality (3.2 and 2.5, respectively, see Table 2).
Given the important effect that volume had on survival, it is
important to note that patients who received compliant care had
improved survival irrespective of the volume of the institution
where they were treated (Fig. 3).
Discussion
Overall compliance with NCCN guidelines in California’s large
hospitals was relatively poor, with just over a third of patients
receiving compliant care. The importance of this lies in the fact
that compliant care, when controlled for patient and hospital
factors, was associated with almost a 40% reduction in the risk of
mortality. Improved survival for patients receiving compliant care
Table 1 Study cohort
Characteristics n (%) %
Pancreatic cancer patients
Treated at large hospitals ( 400 beds) 5690
Excluded for lack of adequate staging 1984
Study cohort 3706
Sex
Male 1876 50.6%
Female 1830 49.4%
Race
White 2484 67%
Black 319 8.6%
Hispanic 524 14.1%
Asian/Pacific Islander 379 10.2%
Insurance
Private 1366 36.9%
Medicare 1721 46.5%
Medicaid 303 8.2%
Uninsured 107 2.9%
Unknown 209 5.6%
Treatment hospital
Academic 971 26.2%
Non-academic 2735 73.8%
Teaching 1849 49.9%
Non-teaching 1857 50.1%
Stage
0 17 0.5%
I 291 7.9%
II 952 25.7%
III 395 10.7%
IV 2051 55.3%
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was seen for all stage of cancer, at both academic and non-
academic hospitals, and in high to low case-volume settings.
Physician compliance with the NCCN guidelines for the man-
agement of PC can vary for a number of reasons. These factors can
perhaps be divided into three broad categories: the hospital/
clinical environment, the patient factors and the doctor. The first
of these centres around the availability of infrastructure and
clinical resources. This includes everything from equipment
Figure 1 Compliance rate (green bars) for the 50 large California hospitals, with highest compliance to the left. Blue bars indicate academic
hospitals. The red bars indicate annual case volume
Table 2 Multilevel logistic regression model predicting guideline compliance (pancreas cancer, large and academic hospitals, California
2001–2006)
Variable Odds ratio 95% confidence interval P-value
Patient factors
Female (vs. male) 1.01 0.87–1.16 0.933
Age 45–54 years (vs. < 45) 0.95 0.64–1.42 0.804
Age 55–64 years (vs. < 45) 0.74 0.51–1.10 0.136
Age 65–74 years (vs. < 45) 0.68 0.46–0.99 0.045*
Age 75–84 years (vs. < 45) 0.30 0.20–0.44 <0.0001*
Age > 85years (vs. < 45) 0.10 0.06–0.16 <0.0001*
Black (vs. white) 0.94 0.72–1.22 0.632
Hispanic (vs. white) 0.78 0.62–0.98 0.036*
Asian/Pasific Islander (vs. white) 0.94 0.74–1.19 0.585
Charlson 1 (vs. 0) 0.99 0.79–1.23 0.904
Charlson 2 (vs. 0) 0.64 0.45–0.92 0.015*
Charlson 3 (vs. 0) 1.23 1.05–1.45 0.011*
Income quintile 1 (lowest) vs. 5 (highest) 0.61 0.47–0.80 <0.0001*
Income quintile 2 vs. 5 0.61 0.48–0.78 <0.0001*
Income quintile 3 vs. 5 0.65 0.52–0.80 <0.0001*
Income quintile 4 vs. 5 0.80 0.66–0.98 0.032*
Hospital factors
Academic 1.18 0.85–1.62 0.324
Teaching 0.99 0.76–1.29 0.946
Low volume (1–15; vs. high) 0.72 0.57–0.92 0.007*
Mid volume (16–25; vs. high) 0.82 0.67–1.00 0.050*
Multivariable model was constructed with demographic factors and co-morbidities.
*Indicates significant P-values.
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Figure 2 Kaplan–Meier curve comparing survival of those who received compliant care (green line) vs. non-compliant care (red line) for all
stages (a) and excluding stage IV (b). (P < 0.001 for both)
Table 3 Multilevel logistic regression model predicting of mortality (pancreas cancer treated in large and academic hospitals, California
2001–2006)
Variable Odds ratio 95% confidence interval P-value
Compliance 0.64 0.53–0.77 <0.0001*
Patient factors
Female (vs. male) 0.888 0.75–1.06 0.182
Age 45–54years (vs. < 45) 1.342 0.84–2.15 0.221
Age 55–64 years (vs. < 45) 1.728 1.10–2.71 0.017
Age 65–74 years (vs. < 45) 2.227 1.42–3.49 <0.0001*
Age 75–84 years (vs. < 45) 2.521 1.60–3.97 <0.0001*
Age > 85years (vs. < 45) 5.001 2.84–8.81 <0.0001*
Black (vs. white) 1.049 0.75–1.46 0.777
Hispanic (vs. white) 1.078 0.82–1.41 0.585
Asian/pacific islander (vs. white) 0.810 0.61–1.07 0.140
Charlson 1 (vs. 0) 0.659 0.52–0.84 0.001*
Charlson 2 (vs. 0) 0.834 0.57–1.21 0.343
Charlson 3 (vs. 0) 1.499 1.22–1.83 <0.0001*
Cancer stage
Stage 0 (vs. I) 0.25 0.07–0.95 0.041*
Stage II (vs. I) 1.62 1.22–2.17 0.001*
Stage III (vs. I) 2.77 1.96–3.92 <0.0001*
Stage IV (vs. I) 7.84 5.84–10.52 <0.0001*
Hospital factors
Academic 0.66 0.51–0.84 <0.0001*
Teaching 0.84 0.67–1.06 0.144
Low volume (1–15; vs. high) 3.210 2.39–4.31 <0.0001*
Mid volume (16–25; vs. high) 2.505 1.97–3.18 <0.0001*
*Indicates significant P-values.
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(high-quality cross-sectional imaging and linear accelerator
for radiation) to hospital services (beds, operating rooms and
nursing) to medical expertise (medical and radiation oncology,
and pancreatic surgery). All of these may contribute to variation
in the care delivered, although the impact of each has not been
well characterized. In order to try to limit the effect of this infra-
structure element, we limited our analysis to traditional full-
service hospitals with greater than 400 beds. Physicians working in
the 50 hospitals in California that make up our list should have
access (within their own facility or very nearby) to the means to
provide multimodality care for PC. In addition, certainly the
experience and knowledge of the physician (or more often team of
physicians) caring for a patient also contributes to the likelihood
of providing compliant care. In the present study, it was not found
that academic or teaching hospitals were more likely to be com-
pliant on multilevel analysis. However, higher volume centres
were more likely to give compliant care. This is consistent with
accumulating evidence for a variety of cancers that higher volume
hospitals and cancer centres are more compliant with treatment
guidelines than lower volume centres.28–30
The second factor in the variable delivery of compliant care is
the patient him or herself. We found that older patients were less
likely to get compliant care, which is possibly partly (although
probably not exclusively) related to frailty associated with age. We
also found that Hispanic and lower SES patients were less likely to
get compliant care. Variations in cancer care based on ethnicity
and SES are well documented in previous studies.31,32 Certainly,
the overall health of the patient is probably a principle consider-
ation in decisions surrounding a newly diagnosed PC. Surpris-
ingly, the Charlson score was not uniformly a predictor of
compliant care. While Charlson 1 and 2 patients were less likely to
get compliant care (compared with patients with a Charlson of 0),
Charlson 3 patients were more likely to get compliant care. This
finding requires further investigation, but suggests that pre-
existing comorbidities are not the main barrier to care. The acute
health (or ill health) of the patient would also certainly be a factor
in care decisions.
The third factor in the variation in care is the doctor. Physicians
are notoriously resistant at following guidelines across the entire
spectrum of medical practice.33–35 Specifically for PC, the poor
overall prognosis for the bulk of patients with PC, combined with
the high complications rates historically associated with pancre-
atic surgery,30 may lead some physicians to therapeutic nihilism.
Previous authors have demonstrated that a high percentage of
patients with early stage PC do not undergo surgery.36 Physicians
frequently cite individual patient needs and situational complex-
ity in non-compliance with clinical practice guidelines.33 There is
complexity to the multimodality care of patients with PC, and
certainly care must at times be tailored to the tumour and patient.
However, we sought to define compliance in broad terms to avoid
debates like those between adjuvant vs. neoadjuvant, specific che-
motherapy regimens or chemotherapy vs. chemoradiation. Thus,
within our definition of compliance, certainly wide variation in
practice would be permissible. However, in spite of a low bar,
compliance was poor.
The present study is limited by the very nature of the database.
The nature of a retrospective analysis of secondary data limits our
ability to attribute causality. Specifically, in this study, the ‘true’
stage of patients who did not undergo surgery (and hence are
staged based on radiographic data alone) is less certain. However,
the Kaplan–Meier survival curves by stage in this cohort (despite
only a minority undergoing surgery) are entirely typical (data not
shown). In addition, the radiographical staging is in fact the basis
of clinical care decisions (and thus should be the data underlying
the offer of compliant care). Certainly a portion of patients with
PC will have such a poor performance status on presentation that
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Figure 3 Kaplan–Meier curves comparing survival of stages I–III patients who received compliant care (green line) vs. non-compliant care
(red line) at (from left to right) low- (1–15), medium- (16–25) and high- (>25) volume centres. Improved survival is seen for compliant care in
every setting. (P < 0.001 for all)
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compliant care, based on their radiographical staging alone, is not
feasible because of their poor performance status. This data set
does not allow us to tease out the impact this element has on the
delivery of compliant care. The CCR does not include a measure
of acute performance status (e.g. Karnofsky score). However, we
found a wide variation in compliance across hospitals, although
patients with similar staged cancer would presumably present
suffering similar sequelae from their tumours. Furthermore, while
there are data confirming that performance status impacts short-
term outcomes in pancreas surgery,37,38 and thus undoubtedly
does influence the decision regarding surgical resection, the poor
compliance for even those patients who are clinically Stage I or II
suggests that it was not generally the ill health of the patients that
was the barrier. Performance status does also impact survival for
stage IV disease.39 However, for these patients, the NCCN guide-
lines explicitly recommend Gemcitabine chemotherapy for both
good and poor performance status patients as a Category 1 rec-
ommendation because of the proven palliative benefit.20 Thus,
given the strong correlation we have demonstrated between com-
pliance and patient level outcomes, the lack of a Karnofsky per-
formance measure is likely to represent a small deficiency in the
current analysis.
Patient preferences may affect adherence with guidelines.40
Although this element cannot be directly assessed with respect to
surgical intervention with our data, we have accounted for this
with respect to delivery of chemotherapy. The CCR database does
include a variable noting that chemotherapy was recommended
but not delivered or refused. These patients were coded for our
analysis as having received chemotherapy, so that facilities were
not penalized if patients declined chemotherapy.
The development of quality indicators for PC care has proved
extraordinarily challenging.41 In spite of interest in identifying a
new ‘yardstick,’ the principle measures of quality in PC have, for
some time, been surgical case volume and peri-operative mortal-
ity.42,43 Our data does confirm a clear relationship between case
volume and outcomes. While volume has been a principle indica-
tor of quality for all complex surgery, it remains problematic. The
definition of high volume in the literature varies widely,44 and
patients are not clearly migrating to higher volume centres.9 Pro-
grammes such as NSQIP and UHC-QAP target another quality
metric, post-operative morbidity and mortality complications.
While post-operative complications certainly impact long-term
survival in PC,45 the mere avoidance of complications falls far
short of assessing the multimodality care of the PC patient. Fur-
thermore, a minority of patients with PC go to surgery, so these
outcome measures do not apply. In contrast, compliance with the
NCCN clinical practice guidelines possibly offer a process and
appropriateness measure that is associated with improved out-
comes. Clearly, the NCCN guidelines are not designed at present
to be a quality indicator. They represent a consensus approach to
care pathways to be offered to patients. Quality measures typically
imply that non-compliance is an indicator of poor care. Arguably,
for a portion of the patients in our cohort, the choice against
surgery or chemotherapy was absolutely appropriate. However,
there is little doubt that a gap remains in care. We believe that
motivating physicians to provide compliant care (or explain why
compliant care was not appropriate/offered/accepted in indi-
vidual cases) would improve the overall care of patients with PC.
In conclusion, the present study showed a poor rate of compli-
ance with NCCN guidelines for PC in California’s large hospitals.
Compliance was correlated with decreased mortality. Measures
should be taken to improve compliance in the care of these patients.
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